Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

NCT03642496 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

18

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Malignancies

Interventions

BIOLOGICAL: Low dose ET019002- T Cells
BIOLOGICAL: Middle dose ET019002- T Cells
BIOLOGICAL: High dose ET019002- T Cells

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Collaborators

[object Object]